
Please try another search
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Vladislav Sandler | 60 | 2013 | Co-Founder, CEO & Director |
H. Michael Shepard | 75 | 2018 | Scientific Advisor |
Marc Feldmann | 81 | 2017 | Independent Chairman & Chairman of Advisory Board |
Peter Redmond | 79 | 2015 | Independent Non-Executive Director |
Koen Van Besien | - | 2022 | Clinical Advisor & Medical Director |
Alexis M. Sandler | 49 | 2017 | Independent Co-Founder & Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review